Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Hepatology. 2022 Jun 29;76(6):1634–1648. doi: 10.1002/hep.32490

Fig. 5. Consensus subtypes of HCC in PDX models.

Fig. 5.

A, Expression patterns of PICS100 genes in HCC PDX tumors. PDX tumors (n=75) were stratified according to PICS100.

B, Mice were transplanted with PDX tumors as indicated in Materials and Methods. Mice were then randomized to treatment with vehicle (controls) or sorafenib of 50 mg/kg. P-values (Student t-test) indicate significance of difference at final measurement of tumor size.

C, Depletion of β-catenin expression decreased sorafenib sensitivity in HCC cells. Results of cell viability assays performed 48 h after sorafenib treatment in HepG2 and HuH1 cells transduced with b-catenin-silencing shRNAs (shb-cat-2, shb-cat-4) or a control shRNA against green fluorescent protein (shGFP). Cell viability after sorafenib treatment were compared using a Student t test. Data shown are means ± s.e’s. of the mean from three independent experiments. *P<0.01. **P<0.001